Abstract
AbstractThis data synthesis examined the effectiveness of behavioural and pharmacological approaches for cannabis treatment. We integrated findings from high level evidence studies and prioritised data from Europe when available. The synthesis found that only a relatively small number of published behavioural and pharmacological studies on cannabis interventions have been conducted in Europe. Applying both European and non-European data, it was found that Cognitive Behavioural Therapy (CBT) and/or Motivational Enhancement Therapy (MET) improved short-term outcomes in the frequency of cannabis use and dependency severity, although abstinence outcomes were less consistent. These improvements were typically not maintained nine months after treatment. CBT and MET (or combined CBT + MET) treatments that extend beyond four sessions were more effective than fewer sessions over a shorter duration. Combining CBT or MET (or combined CBT + MET) with adjunctive Contingency Management (CM) improved therapeutic outcomes. No pharmacotherapies have been approved for the management of cannabis use, cannabis use disorders or cannabis withdrawal. Despite only weak evidence to support the use of pharmacological agents, some are used ‘off-label’ to manage withdrawal symptoms outside clinical trials.
Funder
The University of Queensland
Publisher
Springer Science and Business Media LLC
Reference57 articles.
1. EMCDDA (2021). European Drug Report 2021: Trends and Developments
2. United Nations (2020). World Drug Report 2020
3. Degenhardt L, Chiu W-T, Sampson N, Kessler RC, Anthony JC, Angermeyer M, Bruffaerts R, de Girolamo G, Gureje O, Huang Y et al (2008) Toward a global view of alcohol, tobacco, cannabis, and cocaine use: findings from the WHO World Mental Health Surveys. PLoS Med 5:e141. https://doi.org/10.1371/journal.pmed.0050141
4. Kelly AB, Weier M, Hall WD (2019) The age of onset of substance use disorders. In: de Girolamo G, McGorry PD, Sartorius N (eds) Age of onset of mental disorders. Springer International Publishing, Cham, pp 149–167
5. Degenhardt L, Charlson F, Ferrari A, Santomauro D, Erskine H, Mantilla-Herrara A, Whiteford H, Leung J, Naghavi M, Griswold M et al (2018) The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Psychiatry 5:987–1012. https://doi.org/10.1016/S2215-0366(18)30337-7